Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CTX 101 - Crescita Therapeutics

Next Previous
Search
Drug Profile

CTX 101 - Crescita Therapeutics

Alternative Names: CTX-101 - Crescita Therapeutics; Mical (1); Mical 1

Latest Information Update: 19 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nuvo Research
  • Developer Crescita Therapeutics; Ferndale Laboratories
  • Class Antipsoriatics; Corticosteroids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plaque psoriasis
  • No development reported Psoriasis

Most Recent Events

  • 19 Jan 2025 CTX 101 is still in phase III development in Plaque psoriasis in USA (Topical) (Crescita Therapeutics pipeline, January 2024)
  • 25 Apr 2022 CTX 101 is still in phase III development in Plaque psoriasis in USA (Topical) (Crescita Therapeutics pipeline, April 2022)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Psoriasis in Canada (Topical)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top